

The LentiVector® Platform Company
A leader in gene and cell therapy

Oxford BioMedica and Axovant Worldwide Exclusive Licence Agreement for OXB-102 for Parkinson's disease

06 June 2018

Forward-looking statements

This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the “Securities”). Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this presentation have not been formally verified by Oxford BioMedica plc (the “Company”) or any other person. Accordingly, no representation or warranty, expressed or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this presentation, and no reliance should be placed on such information or opinions. Further, the information in this presentation is not complete and may be changed. Neither the Company nor any of its respective members, directors, officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this presentation.

This presentation may contain forward-looking statements that reflect the Company's current expectations regarding future events, its liquidity and results of operations and its future working capital requirements. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the success of the Company's development strategies, the successful and timely completion of clinical studies, securing satisfactory licensing agreements for products, the ability of the Company to obtain additional financing for its operations and the market conditions affecting the availability and terms of such financing.

A world leading gene and cell therapy company

OxfordBioMedica

Growing Market

KYMRIAH (tisagenlecleucel) LUXTURNA (voretigene neparvovec-rzyl) YESCARTA (axicabtagene ciloleucel)

Oxford BioMedica is at the centre of the gene and cell therapy revolution – a growing multi-billion $ market[1]. Three therapies approved in six months and seven more over the next few years.

01

Profitable Platform

NOVARTIS Bioverativ Orchard therapeutics GC LabCell IMMUNE DESIGN

Partnerships with Novartis, Bioverativ, Orchard Therapeutics, GC LabCell and Immune Design.

02

Developing Products

LentiVector Enabled AXOVANT SANOFI

Developing a pipeline of our own assets in key therapeutic areas - to be either spun out or out-licensed. Products and patents licensed to Sanofi and Axovant.

03

[1]Clive Glover, GE Healthcare "Sales of cell and gene therapy will reach $10 billion by 2021", October 2015.

Strategy: Leveraging our LentiVector Enabled delivery platform



OxfordBioMedica

Worldwide Exclusive Licence Agreement for OXB-102 (AXO-Lenti-PD)

Worldwide exclusive licence agreement with AXOVANT

Licence agreement overview

- Worldwide exclusive licensing agreement to develop and commercialise OXB-102 (now named AXO-Lenti-PD) for Parkinson's disease (includes all indications)
- Licence to Oxford BioMedica's LentiVector Enabled technology
- Access to Oxford BioMedica's industrial-scale manufacturing technology
- Intend on putting in place agreements for clinical and commercial supply
- Axovant will be able to harness the full Roivant drug development platform to ensure its rapid development
- Phase I/II study in advanced Parkinson's disease expected to initiate by the end of 2018

Key Terms

- Headline value $842.5 million
- $30 million upfront (including $5m pre-payment for manufacturing services)
- In addition achieve payment of:
  - $55 million for specified development milestones
  - $757.5 million for specified regulatory and sales-related milestones
- 7-10% tiered royalty payable on net sales

Axovant

- Axovant Sciences (NASDAQ: AXON) is a US listed clinical-stage biopharmaceutical company dedicated to advancing treatments for patients with life-altering neurologic conditions
- Their mission is to transform promising therapies into solutions for patients
- Axovant expertise and focus on neurological disorders (including Parkinson's disease) makes them an ideal development and commercialisation partner for OXB-102 (now known as AXO-Lenti-PD)
- Axovant has strong support from its parent Roivant and is perfectly positioned to bring AXO-Lenti-PD to the market as quickly as possible to treat patients with Parkinson's disease

AXOVANT

[1]

Products



Product pipeline

LentiVector Enabled

Product	Indication	Pre-Clinical	Phase I	Phase I/II	Phase II	Phase III	Approval
OXB Proprietary Products							
OXB-202	Corneal graft rejection						
OXB-302	Cancer, multiple						
OXB-201	Wet AMD						
OXB Partnered Products							
AXO-Lenti-PD	Parkinson's disease						
SAR422459	Stargardt disease						
SAR421869	Usher syndrome 1B						

To be spun out or out-licensed

OxfordBioMedica

Development milestones and royalties

AXOVANT

SANOFI

SANOFI

In vivo programmes

Parkinson's disease remains an area of high unmet medical need

- Parkinson's disease (PD) is a progressive neurodegenerative disorder resulting in the loss of dopamine in the striatum
- Motor symptoms can include tremor, rigidity, and bradykinesia
- PD affects approximately 1% of adults over the age of 60, or 7-10 million patients worldwide
- Current standard of care is primarily oral L-dopa. However, significant unmet need exists in treated patients:
  - Waning efficacy over time
  - Fluctuations between ON and OFF states
  - Dyskinesias



AXO-Lenti-PD (formerly OXB-102): a novel gene therapy for Parkinson's disease

- AXO-Lenti-PD contains three genes that encode the critical enzymes required for dopamine synthesis
  - **Tyrosine hydroxylase (TH):** converts tyrosine to L-dopa
  - **Cyclohydrolase 1 (CH1):** rate-limiting enzyme for synthesis of critical cofactor in TH activity
  - **Aromatic L-amino acid decarboxylase (AADC):** converts L-dopa to dopamine



- Lentiviral vector system with large gene packaging capacity
  - Permits delivery of multiple transgenes at once

- One-time MRI-guided stereotactic delivery into the putamen

AXO-Lenti-PD (formerly OXB-102) : designed to reduce motor fluctuations in Parkinson's disease



AXO-Lenti-PD's novel 3-gene therapy approach is designed to (1) increase basal dopamine production and (2) reduce dopamine variability

GOALS OF THERAPY:

- Less troublesome dyskinesia
- Less OFF time
- More ON time
- Lower requirement for exogenous L-dopa

* Theoretical benefits based on postulated mechanism of action (not data from investigational studies)

ProSavin®(OXB-101) multiple doses evaluated in Phase I/II study

Mean Improvement in UPDRS-III (OFF) Score at 12 Months



- **All patients (N=15): Mean improvement from baseline of 11.8 points at 12 months (p=0.0001)**

Cohort 1 (low dose): 1.9 x 10^7 TU

Cohort 2a and 2b (mid dose): 4.0 x 10^7 TU

Cohort 3 (high dose): 1.0 x 10^8 TU

Source: Palfi S, Gurruchaga JM, et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. The Lancet. January 2014. http://dx.doi.org/10.1016/S0140-6736(13)61939-X
Figure shows mean change in UPDRS III score OFF medication relative to baseline at 12 month for each cohort. Error bars show standard error. UPDRS = Unified Parkinson's Disease Rating Scale. Wilcoxon signed-rank paired test is used to compare the difference of UPDRS scores at 6 or 12 months versus baseline.

OxfordBioMedica

ProSavin®(OXB-101) sustained response observed several years after administration



- Durable effects seen through 4 years after one-time administration of ProSavin®
- UPDRS-III (OFF) scores are typically expected to worsen by 3-4 points/year* in this population

Mean UPDRS III (OFF) scores pooled across low, mid, and high cohorts. Number of subjects: 15 (baseline to 24 months), 14 (24 months), 11 (36 and 48 months), Assessments post-deep brain stimulation (DBS) are excluded (n=3)

*Source: Palfi S, Gurruchaga JM, et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. The Lancet. January 2014. http://dx.doi.org/10.1016/S0140-6736(13)61939-X.

OxfordBioMedica

AXO-Lenti-PD (formerly OXB-102): a re-engineered gene therapy product

AXO-Lenti-PD achieves up to 10-fold increases in dopamine + L-dopa production compared to ProSavin® (OXB-101), without impacting infusion volume or rate of administration

- **AXO-Lenti-PD was the product of multifactorial experimentation to modify the genetic payload to improve dopamine production**
  - Different ordering of transgenes
  - Balanced stoichiometry of gene expression to ensure consistent 1:1 production of TH and CH1
  - Fusion of TH and CH1 with flexible linker



Source: Palfi S, Gurruchaga JM, et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. The Lancet. January 2014. http://dx.doi.org/10.1016/S0140-6736(13)61939-X

OxfordBioMedica

AXO-Lenti-PD (formerly OXB-102): increases catecholamine production compared to ProSavin® (OXB-101)



AXO-Lenti-PD achieved up to 10-fold increases in dopamine + L-Dopa production compared to ProSavin®

Platform

Platform pipeline

LentiVector Enabled

Product	Indication	Pre-Clinical	Phase I	Phase I/II	Phase II	Phase III	Approval
LentiVector® platform							
CTL019[1,2]	r/r ALL						
CTL019[1,2]	r/r DLBCL						
2nd CAR-T	Cancer (multiple)						
Factor VIII	Haemophilia A						
Factor IX	Haemophilia B						
OTL-101	ADA severe combined immunodeficiency						
OTL-201	MPS-IIIA						
Other	undisclosed						
Other	undisclosed						
CMB305	Advanced, relapsed or metastatic sarcoma						
LV305	NY-ESO-1 expressing cancers						

Process development and bioprocessing revenues, and royalties

NOVARTIS

Bioverativ

Orchard therapeutics

IMMUNE DESIGN

In vivo programmes

[1] USAN name is tisagenlecleucel
[2] Approved in the US only

OxfordBioMedica

Summary

Expected news flow

Partners' programmes

Novartis

2nd CAR-T programme to enter clinic

Royalty stream from Novartis/CTL019[1] increasing in 2018

Expected EMA approval for paediatric r/r ALL and adult r/r DLBCL in EU in H1 2018

Orchard Therapeutics

Intends to file a BLA for ADA-SCID during H2 2018

Bioverativ

Bioverativ gene therapy product for haemophilia A & B progressing towards clinical development material by end of 2018

LentiVector® delivery platform

Further contracts with new and existing partners giving us long-term economic interest in partners' product candidates by end of 2018

Invest in further development of platform to improve the volume and yield from bioprocessing and efficacy of vector transduction of target cells during 2018

In-house products

Advancement of AXO-Lenti-PD (formerly OXB-102) for Parkinson's disease into clinical development by Axovant - expected before year end 2018

Spin out / out-license of at least one in-house product candidates in H2 2018

[1] USAN name is tisagenlecleucel

A world leading gene and cell therapy company

Growing Market

KYMRIAH (tisagenlecleucel) LUXTURNA (voretigene neparvovec-rzyl) YESCARTA (axicabtagene ciloleucel)

Oxford BioMedica is at the centre of the gene and cell therapy revolution – a growing multi-billion $ market[1]. Three therapies approved in six months and seven more over the next few years.

01

Profitable Platform

NOVARTIS Bioverativ Orchard therapeutics GC LabCell IMMUNE DESIGN

Partnerships with Novartis, Bioverativ, Orchard Therapeutics, GC LabCell and Immune Design.

02

Developing Products

LentiVector Enabled AXOVANT SANOFI

Developing a pipeline of our own assets in key therapeutic areas - to be either spun out or out-licensed. Products and patents licensed to Sanofi and Axovant.

03

[1]Clive Glover, GE Healthcare "Sales of cell and gene therapy will reach $10 billion by 2021", October 2015.

Contact Us

Oxford BioMedica plc
Windrush Court
Transport Way
Oxford
OX4 6LT

John Dawson, CEO

Stuart Paynter, CFO

Tel: +44 (0) 1865 783 000
enquiries@oxfordbiomedica.co.uk

www.oxfordbiomedica.co.uk

OxfordBioMedica